For many women diagnosed with early-stage breast cancer, the decision to undergo chemotherapy is a heavy one. It is often used to lower the risk of the cancer returning. However, a new look at data from a large trial involving 868 patients suggests that for some specific groups, the actual benefit of chemotherapy might be very small.
Researchers looked at women over age 50 with early-stage, hormone-positive breast cancer. They specifically looked at patients who had high-risk features, such as tumors larger than 2 centimeters or tumors that had spread to nearby lymph nodes. In these groups, the difference in survival rates between those who received chemotherapy and those who did not was very small, ranging from less than 1 percent to a negligible difference.
It is important to note that this was an exploratory analysis, meaning it is a deep dive into specific groups rather than a primary study. While the results show that certain genetic markers can help predict how a patient might do, the actual benefit of chemotherapy in these high-risk subgroups was small. Patients should talk to their doctors to understand how these findings apply to their specific diagnosis.
